DBVT News and Press, DBV Technologies S.A. From 01/02/23

Summary I explain why I've added Organigram to my tax loss selling basket. I also review the company's performance and risks. Finally, I recap my entire 2022 tax loss selling basket of stocks, some of which I didn't have time to write up individually. Tax Loss Selling Strategy...

DBV Technologies ( NASDAQ: DBVT ) ( OTC:DBVTF ) said the U.S. Food and Drug Administration (FDA) lifted a partial clinical hold on its phase 3 trial which will evaluate the modified Viaskin Peanut 250 μg patch (DBV712) to treat children aged four years to seven years w...

Montrouge, France, December 23, 2022 DB V Technologies Announces FDA H as Lift ed Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial DBV expects to initiate patient screening in Q1 2023 with the last patient screened by 1H 2024 a...

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 3 0 Novem bre 202 2 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place...

Montrouge, France, November 9, 2022 DB V Technologies to Highlight New Clinical Data at ACAAI 2022 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that ...

DBV Technologies S.A. (DBVT) Q3 2022 Earnings Conference Call November 04, 2022 5:00 PM ET Company Participants Anne Pollak – Investor Relations Daniel Tassé – Chief Executive Officer Pharis Mohideen – Chief Medical Officer Confere...

DBV Technologies press release ( NASDAQ: DBVT ): Q3 GAAP EPS of -$0.18. Revenue of $2.07M (+56.8% Y/Y). For further details see: DBV Technologies GAAP EPS of -$0.18, revenue of $2.07M

Montrouge, France, November 3, 2022 DBV Technologies Reports Third Quarter Financial Results and Business Update DBV closes Q3 with a cash balance of $213M DBV continues to practice budget discipline measures; cash used in operating activities decreased more than 35% b...

Montrouge, France, October 31, 2022 DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, toda...

Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euron...